Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Article
in En
| MEDLINE
| ID: mdl-36493792
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article